BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 15294960)

  • 1. Ionizing radiation affects human MART-1 melanoma antigen processing and presentation by dendritic cells.
    Liao YP; Wang CC; Butterfield LH; Economou JS; Ribas A; Meng WS; Iwamoto KS; McBride WH
    J Immunol; 2004 Aug; 173(4):2462-9. PubMed ID: 15294960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant adenovirus-transduced dendritic cell immunization in a murine model of central nervous system tumor.
    Broder H; Anderson A; Odesa SK; Kremen TJ; Liau LM
    Neurosurg Focus; 2000 Dec; 9(6):e6. PubMed ID: 16817689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation of melanoma-specific cytotoxic T lymphocytes by dendritic cells transduced with a MART-1 adenovirus.
    Butterfield LH; Jilani SM; Chakraborty NG; Bui LA; Ribas A; Dissette VB; Lau R; Gamradt SC; Glaspy JA; McBride WH; Mukherji B; Economou JS
    J Immunol; 1998 Nov; 161(10):5607-13. PubMed ID: 9820539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Local irradiation of murine melanoma affects the development of tumour-specific immunity.
    Liao YP; Wang CC; Schaue D; Iwamoto KS; McBride WH
    Immunology; 2009 Sep; 128(1 Suppl):e797-804. PubMed ID: 19740341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Melanoma-reactive class I-restricted cytotoxic T cell clones are stimulated by dendritic cells loaded with synthetic peptides, but fail to respond to dendritic cells pulsed with melanoma-derived heat shock proteins in vitro.
    Fleischer K; Schmidt B; Kastenmüller W; Busch DH; Drexler I; Sutter G; Heike M; Peschel C; Bernhard H
    J Immunol; 2004 Jan; 172(1):162-9. PubMed ID: 14688322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation of T-cell immunity to a murine melanoma using MART-1-engineered dendritic cells.
    Ribas A; Butterfield LH; Hu B; Dissette VB; Chen AY; Koh A; Amarnani SN; Glaspy JA; McBride WH; Economou JS
    J Immunother; 2000 Jan; 23(1):59-66. PubMed ID: 10687138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retrovirally transduced human dendritic cells can generate T cells recognizing multiple MHC class I and class II epitopes from the melanoma antigen glycoprotein 100.
    Lapointe R; Royal RE; Reeves ME; Altomare I; Robbins PF; Hwu P
    J Immunol; 2001 Oct; 167(8):4758-64. PubMed ID: 11591807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antigen presentation by MART-1 adenovirus-transduced interleukin-10-polarized human monocyte-derived dendritic cells.
    Mehrotra S; Chhabra A; Chakraborty A; Chattopadhyay S; Slowik M; Stevens R; Zengou R; Mathias C; Butterfield LH; Dorsky DI; Economou JS; Mukherji B; Chakraborty NG
    Immunology; 2004 Dec; 113(4):472-81. PubMed ID: 15554925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HLA-A2.1/K(b) transgenic murine dendritic cells transduced with an adenovirus encoding human gp100 process the same A2.1-restricted peptide epitopes as human antigen-presenting cells and elicit A2.1-restricted peptide-specific CTL.
    Yang S; Linette GP; Longerich S; Roberts BL; Haluska FG
    Cell Immunol; 2000 Aug; 204(1):29-37. PubMed ID: 11006015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MART-1 adenovirus-transduced dendritic cell immunization in a murine model of metastatic central nervous system tumor.
    Broder H; Anderson A; Kremen TJ; Odesa SK; Liau LM
    J Neurooncol; 2003; 64(1-2):21-30. PubMed ID: 12952283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD40 cross-linking bypasses the absolute requirement for CD4 T cells during immunization with melanoma antigen gene-modified dendritic cells.
    Ribas A; Butterfield LH; Amarnani SN; Dissette VB; Kim D; Meng WS; Miranda GA; Wang HJ; McBride WH; Glaspy JA; Economou JS
    Cancer Res; 2001 Dec; 61(24):8787-93. PubMed ID: 11751400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients.
    Akiyama Y; Maruyama K; Tai S; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K
    Int J Oncol; 2008 Sep; 33(3):433-41. PubMed ID: 18695871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells.
    André F; Chaput N; Schartz NE; Flament C; Aubert N; Bernard J; Lemonnier F; Raposo G; Escudier B; Hsu DH; Tursz T; Amigorena S; Angevin E; Zitvogel L
    J Immunol; 2004 Feb; 172(4):2126-36. PubMed ID: 14764678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KBMA Listeria monocytogenes is an effective vector for DC-mediated induction of antitumor immunity.
    Skoberne M; Yewdall A; Bahjat KS; Godefroy E; Lauer P; Lemmens E; Liu W; Luckett W; Leong M; Dubensky TW; Brockstedt DG; Bhardwaj N
    J Clin Invest; 2008 Dec; 118(12):3990-4001. PubMed ID: 19033668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens.
    Kaplan JM; Yu Q; Piraino ST; Pennington SE; Shankara S; Woodworth LA; Roberts BL
    J Immunol; 1999 Jul; 163(2):699-707. PubMed ID: 10395660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor-specific CD4+ T cells are activated by "cross-dressed" dendritic cells presenting peptide-MHC class II complexes acquired from cell-based cancer vaccines.
    Dolan BP; Gibbs KD; Ostrand-Rosenberg S
    J Immunol; 2006 Feb; 176(3):1447-55. PubMed ID: 16424172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrovirally transduced bone marrow-derived dendritic cells require CD4+ T cell help to elicit protective and therapeutic antitumor immunity.
    De Veerman M; Heirman C; Van Meirvenne S; Devos S; Corthals J; Moser M; Thielemans K
    J Immunol; 1999 Jan; 162(1):144-51. PubMed ID: 9886380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma.
    Goldszmid RS; Idoyaga J; Bravo AI; Steinman R; Mordoh J; Wainstok R
    J Immunol; 2003 Dec; 171(11):5940-7. PubMed ID: 14634105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of antitumor immunization to a defined melanoma antigen using genetically engineered murine dendritic cells.
    Ribas A; Butterfield LH; McBride WH; Dissette VB; Koh A; Vollmer CM; Hu B; Chen AY; Glaspy JA; Economou JS
    Cancer Gene Ther; 1999; 6(6):523-36. PubMed ID: 10608349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of impaired antitumor immunity by fusion of MHC class II-deficient dendritic cells with tumor cells.
    Tanaka Y; Koido S; Ohana M; Liu C; Gong J
    J Immunol; 2005 Feb; 174(3):1274-80. PubMed ID: 15661883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.